These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 28837941)

  • 21. Risperidone-induced Pisa syndrome.
    Harada K; Sasaki N; Ikeda H; Nakano N; Ozawa H; Saito T
    J Clin Psychiatry; 2002 Feb; 63(2):166. PubMed ID: 11874220
    [No Abstract]   [Full Text] [Related]  

  • 22. Risperidone induced ventricular tachycardia.
    Mazhar MN; Resch DS
    Psychopharmacol Bull; 2010; 43(3):82-3. PubMed ID: 21150847
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risperidone long-acting injection: a brief overview.
    Lemon M
    S D J Med; 2004 May; 57(5):171-2. PubMed ID: 15181859
    [No Abstract]   [Full Text] [Related]  

  • 24. [Urinary retention with risperidone].
    Siepmann M; Olbrich H
    Psychiatr Prax; 1997 Jul; 24(4):209. PubMed ID: 9340666
    [No Abstract]   [Full Text] [Related]  

  • 25. Risperidone-induced tardive dyskinesia.
    Hong KS; Cheong SS; Woo JM; Kim E
    Am J Psychiatry; 1999 Aug; 156(8):1290. PubMed ID: 10450277
    [No Abstract]   [Full Text] [Related]  

  • 26. Long-acting risperidone and oral antipsychotics in unstable schizophrenia.
    Rosenheck RA; Krystal JH; Lew R; Barnett PG; Fiore L; Valley D; Thwin SS; Vertrees JE; Liang MH;
    N Engl J Med; 2011 Mar; 364(9):842-51. PubMed ID: 21366475
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Risperidone and edema: apropos of a case].
    Masson M; Elayli R; Verdoux H
    Encephale; 2000; 26(3):91-2. PubMed ID: 10951912
    [No Abstract]   [Full Text] [Related]  

  • 28. An atypical long-acting injectable antipsychotic: implications for pharmacotherapy of schizophrenia.
    Dursun S
    J Psychopharmacol; 2005 Sep; 19(5 Suppl):3-4. PubMed ID: 16144780
    [No Abstract]   [Full Text] [Related]  

  • 29. Olanzapine vs. other antipsychotics in actual out-patient settings: six months tolerability results from the European Schizophrenia Out-patient Health Outcomes study.
    Lambert M; Haro JM; Novick D; Edgell ET; Kennedy L; Ratcliffe M; Naber D
    Acta Psychiatr Scand; 2005 Mar; 111(3):232-43. PubMed ID: 15701108
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antipsychotic treatment discontinuation in previously untreated patients with schizophrenia: 36-month results from the SOHO study.
    Haro JM; Novick D; Suarez D; Roca M
    J Psychiatr Res; 2009 Jan; 43(3):265-73. PubMed ID: 18644606
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Insulin resistance index and counter-regulatory factors during olanzapine or risperidone administration in subjects with schizophrenia.
    Baptista T; Martinez M; Lacruz A; Arellano A; Mendoza S; Beaulieu S; Hernández L; Contreras Q; Galeazzi T; Vargas D
    Schizophr Res; 2007 Jan; 89(1-3):350-2. PubMed ID: 17029751
    [No Abstract]   [Full Text] [Related]  

  • 32. Effect of risperidone on ghrelin and glucose in schizophrenia.
    Cohen D
    Psychiatry Clin Neurosci; 2007 Oct; 61(5):576. PubMed ID: 17875041
    [No Abstract]   [Full Text] [Related]  

  • 33. Acute confusional states during treatment with risperidone.
    Doig A; Sembhi S; Livingston G
    Int J Geriatr Psychiatry; 2000 Jun; 15(6):534-5. PubMed ID: 10861920
    [No Abstract]   [Full Text] [Related]  

  • 34. Hyperprolactinemia with low dose of risperidone in a young female.
    Boothby A; Shad MU
    Asian J Psychiatr; 2017 Jun; 27():69-70. PubMed ID: 28558899
    [No Abstract]   [Full Text] [Related]  

  • 35. Adverse effects of risperidone on spatial working memory in first-episode schizophrenia.
    Reilly JL; Harris MS; Keshavan MS; Sweeney JA
    Arch Gen Psychiatry; 2006 Nov; 63(11):1189-97. PubMed ID: 17088499
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risperidone-induced recurrent giant urticaria.
    Mishra B; Saddichha S; Kumar R; Akhtar S
    Br J Clin Pharmacol; 2007 Oct; 64(4):558-9. PubMed ID: 17880358
    [No Abstract]   [Full Text] [Related]  

  • 37. Risperidone long-acting therapy prescribing patterns and their impact on early discontinuation of treatment in a large Medicaid population.
    Boaz TL; Constantine RJ; Robst J; Becker MA; Howe AM
    J Clin Psychiatry; 2011 Aug; 72(8):1079-85. PubMed ID: 21034690
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risperidone-induced priapism.
    Makesar D; Thome J
    World J Biol Psychiatry; 2007; 8(1):45-7. PubMed ID: 17366350
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study.
    Wang X; Savage R; Borisov A; Rosenberg J; Woolwine B; Tucker M; May R; Feldman J; Nemeroff CB; Miller AH
    J Psychiatr Res; 2006 Oct; 40(7):669-76. PubMed ID: 16762371
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dose-dependent acute excessive weight gain and metabolic changes in a drug-naive patient on risperidone are reversible with discontinuation: a case report.
    Sahoo S; Mishra B; Akhtar S
    Br J Clin Pharmacol; 2007 Nov; 64(5):715-6. PubMed ID: 17509037
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.